Edwards Lifesciences Shares Jump 6.2% After Promising TAVR Data Unveiled at New York Valves Conference

Edwards Lifesciences (NYSE: EW) saw its shares rise 6.2% after the company showcased a wide range of new clinical evidence at the New York Valves conference in late June 2026. The data, spanning its aortic, mitral and tricuspid transcatheter valve therapies, reinforced the company’s long-term strategy around earlier and less invasive interventions for structural heart disease.

Among the most closely watched presentations were the baseline characteristics from the PROGRESS trial, which focused on moderate aortic stenosis, and the seven-year durability results of the SAPIEN 3 valve from the PARTNER 3 study. These findings deepen the clinical rationale for expanding transcatheter aortic valve replacement (TAVR) into lower-risk and earlier-stage patient populations — a regulatory and guideline shift that Edwards has been actively pursuing.

The conference also featured updates from the EARLY TAVR, PASCAL and SAPIEN M3 programs, demonstrating Edwards’ efforts to build a comprehensive portfolio across the three main heart valves. While the data do not immediately alter near-term financial expectations, they strengthen the narrative that broader indications and earlier treatment pathways are becoming more evidence-based.

However, investors remain focused on the path to securing formal guideline updates and reimbursement policies for early TAVR, as well as managing rising research and development costs and tariff-related margin pressure. Edwards has projected $8.3 billion in revenue and $2.2 billion in earnings by 2029, implying annual revenue growth of roughly 9.6% and a near doubling of current earnings. Achieving those targets will require both clinical success and operational discipline.

Private investor fair value estimates, gathered by Simply Wall St, cluster tightly between $91.90 and $96.92 per share — a range that underscores how much hinges on the company’s ability to deliver on early TAVR expansion. With the stock trading near the top end of that range after the conference, the market is already pricing in a high probability of favorable regulatory outcomes.

This article is for informational purposes only and does not constitute investment advice. The data and analysis are based on publicly available information and historical trends. Always conduct your own research before making investment decisions.